Skip to main content

Table 3 Subgroup analysis by study population

From: Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials

Subgroups Number of studies (number of patients) Risk ratio of AKI (95% CI) P -value (test for effect) Heterogeneity
ARDS 4 (919) 1.55 (1.15 to 2.09) 0.005 I 2 = 0%
Non-ARDS 6 (418) 0.90 (0.49 to 1.67) 0.75 I 2 = 0%
Surgery 4 (289) 0.89 (0.45 to 1.75) 0.73 I 2 = 0%
Sepsis 1 (49) 1.77 (0.17 to 18.26) 0.63 Not applicable
Pediatric hypoxemic respiratory failure 1 (80) 0.67 (0.10 to 4.49) 0.68 Not applicable
  1. AKI, acute kidney injury; ARDS, acute respiratory distress syndrome.